S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
S&P 500   3,375.59 (+0.06%)
DOW   27,931.72 (+0.13%)
QQQ   272.23 (-0.09%)
AAPL   458.10 (-0.42%)
MSFT   208.73 (+0.01%)
FB   260.59 (-0.27%)
GOOGL   1,511.78 (-0.32%)
AMZN   3,147.00 (-0.44%)
NVDA   461.27 (+0.78%)
CGC   17.27 (-0.29%)
BABA   252.77 (-0.37%)
TSLA   1,641.90 (+1.29%)
GE   6.65 (+0.76%)
MU   46.02 (-0.26%)
AMD   81.07 (-0.94%)
T   30.02 (+0.37%)
F   7.08 (+0.71%)
ACB   10.76 (+5.70%)
GILD   68.61 (+0.63%)
NFLX   482.02 (+0.14%)
DIS   130.35 (-0.47%)
BAC   26.54 (+0.72%)
BA   177.79 (+1.75%)
Log in

NASDAQ:ETTXEntasis Therapeutics Stock Price, Forecast & News

$2.89
-0.01 (-0.34 %)
(As of 08/14/2020 01:18 PM ET)
Add
Compare
Today's Range
$2.88
Now: $2.89
$2.91
50-Day Range
$2.62
MA: $3.03
$4.03
52-Week Range
$1.75
Now: $2.89
$9.25
Volume1,598 shs
Average Volume91,679 shs
Market Capitalization$42.23 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETTX
CUSIPN/A
CIKN/A
Phone781-810-0120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7 million
Book Value$3.17 per share

Profitability

Net Income$-43,850,000.00

Miscellaneous

EmployeesN/A
Market Cap$42.23 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$2.89
-0.01 (-0.34 %)
(As of 08/14/2020 01:18 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

How has Entasis Therapeutics' stock price been impacted by COVID-19?

Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ETTX shares have decreased by 30.0% and is now trading at $2.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Entasis Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Entasis Therapeutics
.

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Entasis Therapeutics
.

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.06.
View Entasis Therapeutics' earnings history
.

What price target have analysts set for ETTX?

6 brokerages have issued 1-year target prices for Entasis Therapeutics' stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Entasis Therapeutics' stock price to reach $7.00 in the next year. This suggests a possible upside of 142.2% from the stock's current price.
View analysts' price targets for Entasis Therapeutics
.

Has Entasis Therapeutics been receiving favorable news coverage?

News stories about ETTX stock have been trending somewhat negative on Friday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Entasis Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.
View the latest news about Entasis Therapeutics
.

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 17,700 shares, a decline of 26.6% from the June 15th total of 24,100 shares. Based on an average daily volume of 122,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.6% of the shares of the stock are sold short.
View Entasis Therapeutics' Short Interest
.

Who are some of Entasis Therapeutics' key competitors?

What other stocks do shareholders of Entasis Therapeutics own?

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the following people:
  • Manoussos Perros, President, Chief Executive Officer & Director
  • Mike Gutch, Chief Financial Officer & Chief Business Officer
  • Ruben Tommasi, Chief Scientific Officer
  • Robin Isaacs, Chief Medical Officer
  • John Mueller, Chief Development Officer

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an IPO on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

Who are Entasis Therapeutics' major shareholders?

Entasis Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Janney Montgomery Scott LLC (0.38%) and Raymond James Financial Services Advisors Inc. (0.16%). Company insiders that own Entasis Therapeutics stock include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo, Innoviva, Inc and Nicholas Galakatos.
View institutional ownership trends for Entasis Therapeutics
.

Which major investors are buying Entasis Therapeutics stock?

ETTX stock was bought by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Entasis Therapeutics stock in the last two years include Group Holdings (Sbs) Advis Tpg, Holdings A/S Novo, Innoviva, Inc, and Nicholas Galakatos.
View insider buying and selling activity for Entasis Therapeutics
.

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $2.89.

How big of a company is Entasis Therapeutics?

Entasis Therapeutics has a market capitalization of $42.23 million and generates $7 million in revenue each year. The company earns $-43,850,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is www.entasistx.com.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at 781-810-0120 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.